PhotoMedex Hits New 12-Month Low at $10.46 (PHMD)
PhotoMedex (NASDAQ:PHMD) shares reached a new 52-week low during trading on Friday , AnalystRatings.Net reports. The stock traded as low as $10.46 and last traded at $10.70, with a volume of 38,205 shares traded. The stock had previously closed at $10.79.
PHMD has been the subject of a number of recent research reports. Analysts at Ascendiant Capital Markets downgraded shares of PhotoMedex from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. They now have a $18.00 price target on the stock. Separately, analysts at Maxim Group downgraded shares of PhotoMedex from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. They now have a $20.00 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of PhotoMedex from $17.00 to $15.00 in a research note on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $16.73.
The stock has a 50-day moving average of $11.65 and a 200-day moving average of $13.59. The company has a market cap of $203.3 million and a price-to-earnings ratio of 19.98.
PhotoMedex (NASDAQ:PHMD) last announced its earnings results on Monday, May 12th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by $0.02. The company had revenue of $50.10 million for the quarter, compared to the consensus estimate of $56.53 million. The company’s revenue for the quarter was down 12.4% on a year-over-year basis. On average, analysts predict that PhotoMedex will post $0.20 earnings per share for the current fiscal year.
PhotoMedex, Inc (NASDAQ:PHMD) is a Global Skin Health Solutions company that provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.